DDInter662 DDInter1592
Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932. Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism. The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 194
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Ergocalciferol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifapentine (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) resembles Rifapentine (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Ergocalciferol (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Ergocalciferol (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)